Agilent said net revenue for the 3 and 9 months ended July 31, 2025 was $1,738 million and $5,087 million, respectively, an increase of 10% and 6%, respectively, compared to the same periods last year. Revenue from the BIOVECTRA acquisition contributed approximately 2 percentage points in both periods.

1. 01

   Agilent said net revenue for the 3 and 9 months ended July 31, 2025 was $1,738 million and $5,087 million, respectively, an increase of 10% and 6%, respectively, compared to the same periods last year. Revenue from the BIOVECTRA acquisition contributed approximately 2 percentage points in both periods.

2. 02

   The company said net income for the 3 months was $336 million compared to $282 million for the same period last year, and net income for the 9 months was $869 million compared to $938 million for the same period last year. Cash provided by operating activities for the 9 months was $1,014 million compared to $1,270 million for the same period last year.

3. 03

   Agilent said total gross margin for the 3 months decreased 3 percentage points compared to the same period last year, citing higher tariffs and shipping costs as factors. It also said tariff changes in Q3 adversely impacted its cost of revenue and it expects to substantially mitigate the impact during fiscal year 2026.

4. 04

   The company said it paid cash dividends of $0.744 per share, or $212 million in total, during the 9 months. Under the 2023 repurchase program, it repurchased and retired 2.734 million shares for $340 million, and as of July 31 had remaining authorization to repurchase approximately $34 million of common stock.

Key figures

Quarter ended July 31, 2025

Revenue

$1.7B

Operating income

$360M

Net income

$336M

EPS

$1.18

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.